Genenta Announced That The Licence Agreement With Ospedale San Raffaele (Osr) Has Been Amended And Restated To Provide Access To All Solid Tumour Indications, Subject To Governmental Consent As Described Below.This Agreement Will Strengthen The Breadth Of Ip Position And Confirm Options For Combination Treatments And Other Potential Payloads. Promising Preliminary Clinical Data Generated In The Ongoing Study Of The First Solid Tumour Indication In Glioblastoma Supports Decision To Expand The Licence To Cover All Solid Tumours And Primes Ability To Impact Other Hard-To-Treat Cancer Types.The Amended And Restated Licence Agreement Reinforces Genenta'S Long-Term Strategic Relationship With Osr, Contributing To The Unique And Valuable Expertise For The Development Of Cell-Based Therapies
